SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic alliance with the Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The alliance will unite the strength and resources of both parties to accelerate the development of China's biomedical innovation and industrialization.
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.
TJAB, a state of the art pharmaceutical research & development platform, was jointly established by the Ministry of Science and Technology, the Ministry of Commerce, the Ministry of Health, the State Food and Drug Administration, and Tianjin Municipality. It was established with the vision of creating China's International Innovation Zone of Biotechnology and Medicine (BioMed Zone) to boost China's biomedical industry. Situated at the heart of the Tianjin Binhai New Area, TJAB has attracted more than 100 research & development groups, focusing in the areas of infectious diseases, cancer, diabetes, and hypertension.
Under the agreement, TJAB and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by enterprises residing in TJAB. HUYA will also be able to globalize select programs from TJAB through HUYA's innovative co-development model and worldwide pharmaceutical partners.
"TJAB attracts the most promising drug candidates from China and are known to play an important role in promoting novel Chinese drugs to international markets," said Clement Gingras, HUYA's CTO and COO, China. "Collectively, HUYA and TJAB will become a Mecca for drug innovation in China's biomedical sector."
Dr. Zeqi Zhou, Senior Vice President of TJAB, commented, "TJAB aims to become a leading innovation source for the biopharmaceutical industry in China. With HUYA's expertise in guiding China's novel drug development to international standards, this alliance will further promote TJAB's ability to attract top talents and become a world-class core technology platform for new drug development."
ABOUT HUYA BIOSCIENCE INTERNATIONAL
HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com
ABOUT TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE
TJAB is located at the center of the BioMed Zone in the Binhai New Area, Tianjin. The Tianjin Binhai New Area is featured as the third economic growth hotspot in China, following the footsteps of Shenzhen and Shanghai Pudong. With 1.1 billion Yuan (RMB) of investment, this institute has a construction area of 350,000 square meters. The first 70,000 square meters building was ready to use in June 2009. More than 97 leading companies resided in the Academy, with over 100 proprietary projects (foreign projects accounted for approximately 60%) in incubation. Many of these projects are affiliated with the most prestigious universities in China. For more information, please visit www.tjab.org/English
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
Ping Yang, MS
Business Development Manager
HUYA Bioscience International
SOURCE HUYA Bioscience International